Plasma B2M levels are higher in ADC patients compared to non-ADC patients and serves as a risk factor for ADC progression (Sánchez-Portocarrero et al. 1996; Stern et al. 2001); however, it cannot independently predict neurological outcomes following HIV infection (Childs et al. 1999). This evidence concerns the gene B2M and AIDS dementia complex.